However, therapeutic strategies have shifted in recent years with the introduction of novel targeted agents, particularly BCL2 inhibitors and Bruton tyrosine kinase (BTK) inhibitors [3]. CLL can involve any lymphoid tissue in the body, such as the spleen, liver, and, since tonsils are part of the reticuloendothelial system, it is expected that tonsils are commonly involved. Here, BTK is linked to B-cell chronic lymphocytic leukemia.